India-UK Trade Agreement: A Threat to Affordable Medicines

In a busy New Delhi slum, a single mother rummages through the clutter of her modest home, searching for a way to afford her son’s cancer medication. For families like hers, the perilous dance between economic survival and health is a daily struggle. The newly ratified Free Trade Agreement (FTA) between India and the UK threatens to worsen this reality, as experts warn that millions of low-income Indians may soon find life-saving medicines beyond their reach.

A Shift in Power Dynamics

Civil society groups and health experts are raising voices of concern over the implications of the India-UK FTA. At its core, the agreement’s intellectual property (IP) provisions appear to favor multinational pharmaceutical corporations, jeopardizing long-standing mechanisms that enable India to produce affordable generic drugs.

“This isn’t simply about trade,” states Jyotsna Singh, co-convenor of the Working Group on Access to Medicines and Treatments. “It’s about whether a person living on ₹200 (£2) a day can afford cancer treatment or survive tuberculosis.” The stark reality is that lives hang in the balance, and the agreement may tilt the scale in favor of profit over people.

The Controversial IP Provisions

At the heart of the controversy lie provisions that may limit the Indian government’s ability to issue compulsory licenses—legal instruments that allow local companies to manufacture patented drugs at reduced prices during public health crises. India effectively utilized this strategy in 2012 to slash the cost of sorafenib, a cancer medication sold by Bayer under the brand, Nexavar. The result? A staggering 97% price reduction—from ₹2.8 lakh (£2,600) to merely ₹8,800 (£80)—making life-saving treatment accessible to thousands.

• Compulsory Licenses: Tools that can significantly lower drug prices in emergencies.
• Voluntary Licenses: Often come with stipulations and do not guarantee similar price reductions.
• Transparency Concerns: Reduced reporting requirements could obscure patent use data, complicating compulsory licensing applications.

“By discouraging compulsory licensing and promoting voluntary licenses, the deal hands over control of access to medicines to the market,” explains Prof. Biswajit Dhar, a noted trade expert and former professor at Jawaharlal Nehru University. “Voluntary licenses often come with conditions that don’t lead to the same affordability.”

Weakening India’s Patent Safeguards

An alarming element of the FTA includes altered reporting requirements. Under the new rules, firms no longer need to annually disclose how their patents are “worked” in India; instead, they can do so every three years and keep certain information confidential. This lack of transparency, activists argue, erodes the ability to prove that a drug is inaccessible to the public, a critical condition for applying for a compulsory license.

Experts are also wary of the agreement opening doors to ‘evergreening,’ a practice where companies make minor modifications to existing drugs to claim new patents. Although Indian law currently restricts this under Section 3(d) of the Patents Act, K.M. Gopakumar, co-convenor of the Working Group, warns that the FTA’s focus on “harmonisation” of IP standards with Western countries could nullify such protections.

“This is effectively a backdoor entry for TRIPS-plus provisions,” he elucidates, cautioning that it would encourage unnecessary patent grants, prolong monopolies, and delay the introduction of cheaper alternatives.

The Global Impact

India is not just a national player; it produces over 60% of global vaccines and a significant share of affordable generics for low- and middle-income countries. Critics contend that the FTA could stifle this capacity, creating far-reaching consequences beyond India’s borders. “If the largest generic supplier is restricted, it will be poorer countries that suffer the most,” cautions Dr. Anjali Mehta, a health economist who has studied the implications of international trade agreements.

Government’s Stance

The Indian government, however, heralds the FTA as a groundbreaking milestone poised to elevate exports and draw British investments in manufacturing, services, and digital trade. Officials maintain that the treaty has effectively safeguarded the nation’s ability to protect public health interests. “We believe that we have balanced trade benefits with public health priorities,” insists a senior government official who wished to remain anonymous.

Rights groups, nevertheless, remain skeptical. “You cannot negotiate away access to life-saving drugs in the name of free trade,” asserts Gargeya Telakapalli, a public health campaigner based in Hyderabad. “The poorest Indians—those battling cancer, HIV, diabetes, or TB—are being quietly sacrificed.” This ongoing tug-of-war between public health and trade interests ignites a fierce debate over the moral implications of prioritizing economic growth at the cost of human lives.

Broader Implications of the Trade Agreement

The India-UK FTA follows a similar accord signed last year with the European Free Trade Association (EFTA), which also faced backlash for weakening IP safeguards. Analysts suggest this pattern indicates a considerable shift in India’s trade policy as it increasingly seeks to align with Western economies. Yet the pressing question remains: How much access to affordable medicine is India willing to relinquish for the promise of better trade relations?

As the ramifications of this agreement unfold, the stakes are high—not just for India but for countless individuals globally who rely on affordable medicines for their survival. The ongoing battle between trade and health continues, revealing the intricate ties connecting policy, ethics, and human well-being. For now, the hope lies in the voices of those who resist this shift, advocating for policies that prioritize life over profit.

Source: www.itv.com